Suppressing the irrepressible;the use of LHRH antagonist,degarelix,where maximal androgen blockade had failed to achieve effective testosterone suppression in node-positive prostate cancer treated with potentially curative intent
Restricted accessCase reportFirst published online November, 2017
Suppressing the irrepressible;the use of LHRH antagonist,degarelix,where maximal androgen blockade had failed to achieve effective testosterone suppression in node-positive prostate cancer treated with potentially curative intent
BollaMColletteLBlankLet al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet2002; 360: 103–106.
2.
MoroteJOrsolaAPlanasJet al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol2007; 178: 1290–1295.
